title: Managing Patients With Psoriasis in the Busy Clinic: Practical Tips for Health Care Practitioners.
abstract: Psoriasis is a common inflammatory disease with significant comorbidities, whose management can be challenging given the variety of treatment options. It is critical for nurse practitioners, physician assistants, general practitioners, and dermatology trainees to have useful information about the treatment and monitoring of patients with psoriasis. Although certain aspects of care apply to all patients, each therapeutic agent has its own nuances in terms of assessments, dosing, and monitoring. The most appropriate treatment is based not only on disease severity but also on comorbid conditions and concomitant medications. These practitioners are vital in facilitating patient care by thorough understanding of systemic agents, selection criteria, dosing, and recommended monitoring. This article provides high-yield practical pearls on managing patients with moderate to severe psoriasis. It includes case-based discussions illustrating considerations for special populations, such as pregnant women, children, and patients with comorbidities (eg, human immunodeficiency virus infection, hepatitis C, hepatitis B, and history of malignancy).
authors.affiliation: Department of Dermatology, University of Colorado Denver, Aurora, CO, USA aprilarmstrong@post.harvard.edu.
authors.forename: April W
authors.initials: AW
authors.lastname: Armstrong
authors.affiliation: Department of Dermatology, Portland Veterans Affairs Medical Center, Portland, OR, USA.
authors.forename: Lakshi
authors.initials: L
authors.lastname: Aldredge
authors.affiliation: Dermatology Institute and Skin Care Center, Santa Monica, CA, USA Division of Dermatology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
authors.forename: Paul S
authors.initials: PS
authors.lastname: Yamauchi
mesh_terms: D017255:Acitretin / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001688:Biological Products / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use*; D018450:Disease Progression; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007349:Insurance, Health, Reimbursement; D007641:Keratolytic Agents / Q000627:therapeutic use; D055118:Medication Adherence; D008727:Methotrexate / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy*; D000067251:Symptom Flare Up; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D001688:Biological Products; D007166:Immunosuppressive Agents; D007641:Keratolytic Agents; D013792:Thalidomide; D016572:Cyclosporine; D017255:Acitretin; C505730:apremilast; D008727:Methotrexate
keywords: TNF inhibitor; biologics; cyclosporine; methotrexate; psoriasis